Clomifene

Evidence Level: L5

Predicted Indications: 9

Clomifene

Pharmacist Assessment Report

Clomifene: 46,XY disorder of sex development due to testicular steroidogenesis defect

One-Sentence Summary

Clomifene is an oral ovulation-inducing medicine, originally used to treat female infertility. The TxGNN model predicts it may be useful for 46,XY disorder of sex development due to testicular steroidogenesis defect, with a very high model score. However, there are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	46,XY disorder of sex development due to testicular steroidogenesis defect
TxGNN Prediction Score	0.9990
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in the data compiled for this report. Clomifene is a selective estrogen receptor modulator (SERM). It blocks estrogen receptors in the hypothalamus, which reduces negative feedback and raises GnRH, FSH and LH secretion. This is the basis of its use for ovulation induction in female infertility.

The link to the predicted indication is weak. In this condition, the primary defect is an enzymatic block in testicular steroid production, which sits downstream of the gonadotropin axis. Raising LH stimulation is unlikely to correct a block in the enzymes themselves. The high score (0.999) is therefore best read as a TxGNN model (deep learning) prediction, probably driven by shared reproductive-endocrine associations, rather than as evidence of a therapeutic mechanism.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 1211R	Clomid	Tablet containing clomifene citrate 50 mg (oral)	Not listed in the data compiled for this report

Safety Considerations

The data compiled for this report contains no label-based warnings or contraindications. Please refer to the TGA-approved Product Information (PI) for these.

Drug Interactions: Bexarotene, rated Major (DDInter).
Contraindication signals from the knowledge graph (not label text, and to be verified against the PI):
- Hormone-related conditions: polycystic ovary syndrome, endometriosis, endometrial cancer, thyroid disorders (hypothyroidism, hyperthyroidism), adrenal insufficiency and pituitary tumours.
- Ovarian conditions: ovarian cyst and ovarian hyperstimulation syndrome.
- Other conditions: liver disease, gallbladder disease, thrombophlebitis, anxiety and mood-related disorders, and vision disorders including blindness.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or literature (L5), and the mechanism does not plausibly address a downstream testicular steroidogenesis defect. The high score alone is not enough to justify progressing this indication.

To proceed, the following is needed:

Any preclinical or clinical evidence that clomifene-induced gonadotropin stimulation benefits this condition.
Review of whether an enzymatic block could be bypassed by increased LH drive.
Mechanism of action data compiled from an authoritative source such as DrugBank.
TGA Product Information review for warnings and contraindications, particularly in male and paediatric populations, since the approved use is in women.

It overlaps with the existing female infertility indication, so it confirms current use rather than representing true repurposing.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.